UroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC trimmed its holdings in UroGen Pharma Ltd. (NASDAQ:URGN) by 20.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 61,165 shares of the company’s stock after selling 15,634 shares during the quarter. Oak Ridge Investments LLC owned approximately 0.26% of UroGen Pharma worth $651,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Point72 Asset Management L.P. boosted its stake in shares of UroGen Pharma by 120.3% during the second quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock worth $41,099,000 after buying an additional 1,337,257 shares during the period. Millennium Management LLC raised its stake in UroGen Pharma by 2,672.0% during the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock valued at $19,480,000 after acquiring an additional 1,119,019 shares during the last quarter. Vestal Point Capital LP acquired a new stake in UroGen Pharma during the 3rd quarter worth approximately $5,080,000. Great Point Partners LLC grew its stake in shares of UroGen Pharma by 10.9% in the 2nd quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock valued at $48,767,000 after purchasing an additional 285,714 shares during the last quarter. Finally, Stonepine Capital Management LLC purchased a new position in shares of UroGen Pharma in the 3rd quarter valued at approximately $3,560,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Stock Performance

Shares of URGN opened at $10.27 on Monday. The company has a market capitalization of $240.83 million, a PE ratio of -3.26 and a beta of 1.09. UroGen Pharma Ltd. has a 52-week low of $9.78 and a 52-week high of $20.70. The company has a 50-day simple moving average of $11.39 and a 200-day simple moving average of $13.10. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.29. The company had revenue of $25.20 million during the quarter, compared to analysts’ expectations of $24.22 million. During the same period last year, the business posted ($0.68) earnings per share. Equities research analysts predict that UroGen Pharma Ltd. will post -3.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on URGN. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a report on Wednesday, January 15th. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a research note on Tuesday, October 15th. Finally, Oppenheimer restated an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a research report on Wednesday, October 16th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, UroGen Pharma has an average rating of “Buy” and a consensus price target of $43.70.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.